학술논문
Mouth opening in systemic sclerosis: A longitudinal analysis from the French national cohort study.
Document Type
Article
Author
Chaigne, Benjamin; Bense, Alexandre; Agard, Christian; Allanore, Yannick; Pugnet, Grégory; Hachulla, Eric; Avouac, Jérôme; Bienvenu, Boris; Palat, Sylvain; Grange, Claire; Berthier, Sabine; Chatelus, Emmanuel; Rivière, Sébastien; Truchetet, Marie‐Elise; Kahn, Jean‐Emmanuel; Maurier, Francois; Diot, Elisabeth; Berezne, Alice; Mouthon, Luc; Amoura, Zahir
Source
Subject
*SYSTEMIC scleroderma
*PULMONARY arterial hypertension
*INTERSTITIAL lung diseases
*COHORT analysis
*
*
*
Language
ISSN
0954-6820
Abstract
Background: Few studies have evaluated mouth opening (MO) in systemic sclerosis (SSc). None have studied MO trajectories. Objective: To study MO trajectories in SSc. Methods: This multicentre study included patients enrolled in the French national SSc cohort with at least one MO assessment, described patients based on MO baseline measure, modelled MO trajectories and associated MO measures with SSc prognosis. Results: We included 1101 patients. Baseline MO was associated with disease severity. On Kaplan–Meier analysis, MO <30 mm was associated with worse 30‐year‐survival (p < 0.01) and risk of pulmonary arterial hypertension (p < 0.05). Individual MO trajectories were heterogenous among patients. The best model of MO trajectories according to latent‐process mixed modelling showed that 88.8% patients had a stable MO trajectory and clustered patients into three groups that predicted SSc survival (p < 0.05) and interstitial lung disease (ILD) occurrence (p < 0.05). The model highlighted a cluster of 9.5% patients with diffuse cutaneous SSc (dcSSc) (p < 0.05) and high but decreasing MO over 1 year (p < 0.0001) who were at increased risk of poor survival and ILD. Conclusion: MO, which is a simple and reliable measure, could be used to predict disease severity and survival in SSc. Although MO remained stable in most SSc patients, dcSSc patients with high but decreasing MO were at risk of poor survival and ILD. [ABSTRACT FROM AUTHOR]